Vikas P. Sukhatme
Research Subjects
Vikas P. Sukhatme has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Barden Chan
2 shared publicationsSujata Kale
2 shared publicationsGlenn A. McDonald
Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA
1 shared publicationGuang Hu
Department of Medicine and Center for Study of the Tumor Microenvironment, Divisions of Nephrology, Hematology-Oncology
1 shared publicationGuoming Zhu
Renal Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
1 shared publication- Imre Kovesdi
VectorLogics, Inc., Birmingham, Alabama, United States of America
1 shared publication
Latest Publications
- Open Access
- 5 March 2003
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 95 (5) , 388-399
In Vitro and In Vivo Induction of Antiangiogenic Activity by Plasminogen Activators and Captopril
Background: Many antiangiogenic molecules are proteolytically cleaved from larger plasma proteins. For example, plasminogen activators cleave plasminogen into plasmin, and plasmin is converted into angiostatin in the presence of sulfhydryl donors. We thus investigated whether the antiangiogenic activity in plasma could be increased by treatment with recombinant tissue plasminogen activator (rt-PA) and the sulfhydryl donor captopril. Methods: Human plasma was treated with rt-PA (10 μg/mL) and/or captopril (1 μM). Angiogenesis was measured in vitro by human endothelial cell tube formation and endothelial cell proliferation and in vivo in mice with the Matrigel plug assay. Angiostatin was removed from treated plasma by affinity chromatography, immunoprecipitation, or ion-exchange chromatography, and the antiangiogenic activity of the depleted plasma was assessed by tube formation. Three cancer patients were treated with rt-PA and captopril, and their pretreatment and post-treatment plasmas were tested for antiangiogenic activity in vitro. Results: Angiogenesis in vitro was stimulated by untreated plasma and inhibited by plasma that had been treated with rt-PA and captopril but was not affected by treatment with rt-PA and/or captopril alone. In vivo angiogenesis in Matrigel plugs was substantially lower in mice treated with rt-PA and captopril than in untreated control mice. Antiangiogenic activity in treated plasma was largely retained after angiostatin was removed: treated plasma inhibited angiogenesis by 64.3% (95% confidence interval [CI] = 46.4% to 82.2%), relative to untreated plasma, and treated plasma depleted of angiostatin by affinity chromatography or immunoprecipitation inhibited angiogenesis by 65.1% (95% CI = 53.8% to 76.4%) or 63.7% (95% CI = 50.9% to 76.5%), respectively. Antiangiogenic activity of plasma from three cancer patients was higher after treatment with rt-PA and captopril than before such treatment. Conclusion: Treatment with rt-PA and captopril induced antiangiogenic activity in vitro and in vivo that appears to be independent of angiostatin.
- 5 March 2003
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 95 (5) , 388-399
Open AccessIn Vitro and In Vivo Induction of Antiangiogenic Activity by Plasminogen Activators and Captopril
Background: Many antiangiogenic molecules are proteolytically cleaved from larger plasma proteins. For example, plasminogen activators cleave plasminogen into plasmin, and plasmin is converted into angiostatin in the presence of sulfhydryl donors. We thus investigated whether the antiangiogenic activity in plasma could be increased by treatment with recombinant tissue plasminogen activator (rt-PA) and the sulfhydryl donor captopril. Methods: Human plasma was treated with rt-PA (10 μg/mL) and/or captopril (1 μM). Angiogenesis was measured in vitro by human endothelial cell tube formation and endothelial cell proliferation and in vivo in mice with the Matrigel plug assay. Angiostatin was removed from treated plasma by affinity chromatography, immunoprecipitation, or ion-exchange chromatography, and the antiangiogenic activity of the depleted plasma was assessed by tube formation. Three cancer patients were treated with rt-PA and captopril, and their pretreatment and post-treatment plasmas were tested for antiangiogenic activity in vitro. Results: Angiogenesis in vitro was stimulated by untreated plasma and inhibited by plasma that had been treated with rt-PA and captopril but was not affected by treatment with rt-PA and/or captopril alone. In vivo angiogenesis in Matrigel plugs was substantially lower in mice treated with rt-PA and captopril than in untreated control mice. Antiangiogenic activity in treated plasma was largely retained after angiostatin was removed: treated plasma inhibited angiogenesis by 64.3% (95% confidence interval [CI] = 46.4% to 82.2%), relative to untreated plasma, and treated plasma depleted of angiostatin by affinity chromatography or immunoprecipitation inhibited angiogenesis by 65.1% (95% CI = 53.8% to 76.4%) or 63.7% (95% CI = 50.9% to 76.5%), respectively. Antiangiogenic activity of plasma from three cancer patients was higher after treatment with rt-PA and captopril than before such treatment. Conclusion: Treatment with rt-PA and captopril induced antiangiogenic activity in vitro and in vivo that appears to be independent of angiostatin.
- Open Access
- 29 July 2002
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 158 (3) , 529-539
Endostatin is a potential inhibitor of Wnt signaling
Endostatin (ES) is a fragment of collagen XVIII that possesses antiangiogenic activity. To gain insight into ES-mediated signaling, we studied the effects of ES RNA on Xenopus embryogenesis and observed developmental abnormalities consistent with impaired Wnt signaling. ES RNA blocked the axis duplication induced by β-catenin, partially suppressed Wnt-dependent transcription, and stimulated degradation of both wild-type and “stabilized” forms of β-catenin, the latter suggesting that ES signaling does not involve glycogen synthase kinase 3. Moreover, ES uses a pathway independent of the Siah1 protein in targeting β-catenin for proteasome-mediated degradation. ES failed to suppress the effects of T cell–specific factor (TCF)-VP16 (TVP), a constitutive downstream transcriptional activator that acts independently of β-catenin. Importantly, these data were replicated in endothelial cells and also in the DLD-1 colon carcinoma cells with the mutated adenomatous polyposis coli protein. Finally, suppression of endothelial cell migration and inhibition of cell cycle by ES were reversed by TVP. Though high levels of ES were used in both the Xenopus and endothelial cell studies and the effects on β-catenin signaling were modest, these data argue that at pharmacological concentrations ES may impinge on Wnt signaling and promote β-catenin degradation.
- 29 July 2002
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 158 (3) , 529-539
Open AccessEndostatin is a potential inhibitor of Wnt signaling
Endostatin (ES) is a fragment of collagen XVIII that possesses antiangiogenic activity. To gain insight into ES-mediated signaling, we studied the effects of ES RNA on Xenopus embryogenesis and observed developmental abnormalities consistent with impaired Wnt signaling. ES RNA blocked the axis duplication induced by β-catenin, partially suppressed Wnt-dependent transcription, and stimulated degradation of both wild-type and “stabilized” forms of β-catenin, the latter suggesting that ES signaling does not involve glycogen synthase kinase 3. Moreover, ES uses a pathway independent of the Siah1 protein in targeting β-catenin for proteasome-mediated degradation. ES failed to suppress the effects of T cell–specific factor (TCF)-VP16 (TVP), a constitutive downstream transcriptional activator that acts independently of β-catenin. Importantly, these data were replicated in endothelial cells and also in the DLD-1 colon carcinoma cells with the mutated adenomatous polyposis coli protein. Finally, suppression of endothelial cell migration and inhibition of cell cycle by ES were reversed by TVP. Though high levels of ES were used in both the Xenopus and endothelial cell studies and the effects on β-catenin signaling were modest, these data argue that at pharmacological concentrations ES may impinge on Wnt signaling and promote β-catenin degradation.
- 1 January 2000
- Vol. 20 (1) , 87-91
Training the academic nephrologist for the new millennium.
Physician-scientists play a key role in bringing basic science advances anticipated in the new millennium to the bedside. However, the existence of such individuals is in jeopardy, the reasons for which are summarized in first part of this article. Solutions to this problem are suggested and specific recommendations are directed at government and private agencies, industry, trainees, mentors, and academic institutions. Time is short and decisive action needs to be taken if we are to reap the full rewards of medical knowledge in the 21st century.
- 1 January 2000
- Vol. 20 (1) , 87-91
Training the academic nephrologist for the new millennium.
Physician-scientists play a key role in bringing basic science advances anticipated in the new millennium to the bedside. However, the existence of such individuals is in jeopardy, the reasons for which are summarized in first part of this article. Solutions to this problem are suggested and specific recommendations are directed at government and private agencies, industry, trainees, mentors, and academic institutions. Time is short and decisive action needs to be taken if we are to reap the full rewards of medical knowledge in the 21st century.
- 1 March 1999
- Published by Wiley in The Journal of Gene Medicine
- Vol. 1 (2) , 103-110
Efficient adenoviral gene transfer to kidney cortical vasculature utilizing a fiber modified vector
Background The αv integrin is present in vascular endothelium, including that of the kidney. It is also upregulated in the presence of inflammatory cytokines and in some neoplasms. In an effort to transduce vascular endothelial cells, we compare in vitro and in vivo adenoviral gene transfer of a vector with a high affinity peptide ligand to the αv integrin incorporated into the fiber coat protein AdZ.F(RGD) to an unmodified vector, AdZ. Methods Cell transduction assays were performed on human umbilical vein endothelial cells (HuVEC) and human pulmonary epithelial cells (A549). In vitro competition assays were performed in the presence of either wild type (F5K) or chimeric (F5K(RGD)) soluble recombinant fiber protein. Transduction efficiency was determined by quantitative β‐galactosidase activity. In vivo gene transfer was compared infusing either AdZ or AdZ.F(RGD) into the left renal artery of the rat and assaying β‐galactosidase staining of the kidney. Gene transfer was also evaluated in the presence of a competitive RGD or control RGE peptide. Results There was a marked increase in transgene expression in HuVEC cells with AdZ.F(RGD) as compared to AdZ. The increased expression with AdZ.F(RGD) was more prominent in the endothelial as opposed to the epithelial cell line. Furthermore pre‐incubation of these cells with either F5K or F5K(RGD) soluble fiber protein markedly decreased β‐galactosidase activity of AdZ, whereas only the F5K(RGD) decreased β‐galactosidase activity of AdZ.F(RGD). AdZ.F(RGD) also resulted in significantly enhanced β‐galactosidase expression in the vascular endothelium of the kidney (for comparable amounts of virus injected) as well as significantly higher gene transfer to cortical vasculature. Coinfusion of an RGD peptide with AdZ.F(RGD) blocked gene transfer whereas a control RGE peptide did not. Conclusion We conclude that incorporating a high affinity peptide ligand into the adenoviral fiber protein can preferentially enhance in vitro and in vivo adenoviral transfection efficiency in endothelial cells. Enhancing transfection efficiency will not only broaden the scope of disease processes addressed with adenoviral vectors but also allow the use of lower titer, thereby limiting toxicity. This vector has additional potential to transduce endothelial cells within tumors or ischemic tissue where αv integrins are upregulated. Copyright © 1999 John Wiley & Sons, Ltd.
- 1 March 1999
- Published by Wiley in The Journal of Gene Medicine
- Vol. 1 (2) , 103-110
Efficient adenoviral gene transfer to kidney cortical vasculature utilizing a fiber modified vector
Background The αv integrin is present in vascular endothelium, including that of the kidney. It is also upregulated in the presence of inflammatory cytokines and in some neoplasms. In an effort to transduce vascular endothelial cells, we compare in vitro and in vivo adenoviral gene transfer of a vector with a high affinity peptide ligand to the αv integrin incorporated into the fiber coat protein AdZ.F(RGD) to an unmodified vector, AdZ. Methods Cell transduction assays were performed on human umbilical vein endothelial cells (HuVEC) and human pulmonary epithelial cells (A549). In vitro competition assays were performed in the presence of either wild type (F5K) or chimeric (F5K(RGD)) soluble recombinant fiber protein. Transduction efficiency was determined by quantitative β‐galactosidase activity. In vivo gene transfer was compared infusing either AdZ or AdZ.F(RGD) into the left renal artery of the rat and assaying β‐galactosidase staining of the kidney. Gene transfer was also evaluated in the presence of a competitive RGD or control RGE peptide. Results There was a marked increase in transgene expression in HuVEC cells with AdZ.F(RGD) as compared to AdZ. The increased expression with AdZ.F(RGD) was more prominent in the endothelial as opposed to the epithelial cell line. Furthermore pre‐incubation of these cells with either F5K or F5K(RGD) soluble fiber protein markedly decreased β‐galactosidase activity of AdZ, whereas only the F5K(RGD) decreased β‐galactosidase activity of AdZ.F(RGD). AdZ.F(RGD) also resulted in significantly enhanced β‐galactosidase expression in the vascular endothelium of the kidney (for comparable amounts of virus injected) as well as significantly higher gene transfer to cortical vasculature. Coinfusion of an RGD peptide with AdZ.F(RGD) blocked gene transfer whereas a control RGE peptide did not. Conclusion We conclude that incorporating a high affinity peptide ligand into the adenoviral fiber protein can preferentially enhance in vitro and in vivo adenoviral transfection efficiency in endothelial cells. Enhancing transfection efficiency will not only broaden the scope of disease processes addressed with adenoviral vectors but also allow the use of lower titer, thereby limiting toxicity. This vector has additional potential to transduce endothelial cells within tumors or ischemic tissue where αv integrins are upregulated. Copyright © 1999 John Wiley & Sons, Ltd.